Fosun International's H1 2025 Revenue Hits RMB87.28 Billion, Profit Attributable to Owners Reaches RMB661.2 Million

Reuters
08/29
Fosun International's H1 2025 Revenue Hits RMB87.28 Billion, Profit Attributable to Owners Reaches RMB661.2 Million

Fosun International Limited has reported its financial results for the first half of 2025, highlighting a total revenue of RMB87.28 billion. The Group noted an industrial operation profit of RMB3.15 billion and a profit attributable to owners of the parent amounting to RMB661.2 million. The Group's four core subsidiaries - Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group - collectively contributed RMB63.61 billion, representing 73% of the total revenue. The company has achieved a significant milestone in its globalization efforts, with overseas revenue now representing 53% of the total revenue. Fosun's total debt to total capital ratio was reported at 53%, maintaining a healthy debt level. Credit rating agency S&P has affirmed Fosun's credit metrics with a "Stable" outlook. Fosun aims to increase its overseas revenue share further while reducing its interest-bearing debt to around RMB60 billion or less. The Group is also focused on achieving RMB10 billion in industrial operation profit and profit attributable to owners of the parent, with plans to gradually increase its dividend payout ratio and elevate its credit rating to an investment-grade level.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10